Leerink reiterates Eli Lilly stock rating on gene therapy progress By Investing.com

Leerink reiterated an Outperform rating and a $1,119 price target on Eli Lilly after the company reported VERVE-102 Phase 1b data showing up to 88% PCSK9 reduction and up to 62% LDL-C reduction from a single dose. Lilly also said it plans to start enrolling a Phase 2 study by year-end, while its broader pipeline remains active with retatrutide obesity data and ongoing VERVE-201 development. Offset somewhat by a $194 million Supreme Court-related legal setback, the headline is still constructive for Lilly's gene-therapy and obesity programs.

Analysis

LLY is increasingly behaving like a platform company rather than a single-product pharma story: the market is paying for a widening set of shots on goal, and gene editing adds a higher-duration optionality layer on top of already elevated obesity and oncology expectations. The key second-order implication is not just incremental pipeline value, but strategic leverage over the lipid market: a credible one-time therapy would pressure chronic injectable and oral LDL-lowering adherence economics, forcing incumbents to compete on convenience, not just efficacy.

From a competitive standpoint, the near-term losers are the entrenched chronic-care franchises whose value proposition depends on long-run refills and physician inertia. If the editing signal holds into Phase 2, payer behavior could shift faster than consensus expects, because a durable therapy creates a budget-category debate: upfront cost versus avoided lifetime CV events. That makes the catalyst path asymmetric over 6-18 months, but also more fragile than the headline efficacy suggests, since safety, redosing uncertainty, and broad-label economics will matter more than raw LDL reduction.

The legal overhang is a real but secondary brake: it does not change the growth narrative, but it can cap multiple expansion when the stock is already rich. The contrarian point is that the market may still be underpricing the portfolio effect of repeated positive readouts — a company with this much clinical momentum can absorb one-off legal noise without derating, unless the obesity data begin to stall or the gene-editing program shows any signal of immunogenicity or durability fade.

For the next few months, the trade is less about calling peak fundamentals and more about whether expectations outrun the cadence of confirmatory data. If Phase 2 enrollment starts on schedule and the obesity program stays clean, the stock can remain structurally supported; if either slips, the valuation multiple has little margin for disappointment.

Key Decisions for Investors

• Stay long LLY into the next 3-6 month catalyst window, but finance with covered calls or a call spread; upside remains intact, but rich valuation means outright delta is expensive.
• Pair trade: long LLY / short a basket of chronic LDL-lowering incumbents (e.g., AMGN or a biotech-heavy basket) for 3-12 months; thesis is that durable, one-time therapy optionality compresses long-duration adherence economics.
• Add a small tactical long in gene-editing exposure only on confirmation of Phase 2 start and clean safety follow-up; best risk/reward is after de-risking, not on the first efficacy print.
• Avoid chasing size here ahead of legal or regulatory headlines; if the stock sells off 5-8% on non-fundamental noise, use it as entry rather than paying up into strength.
• For event-driven accounts, buy a 6-12 month LLY call spread rather than stock if seeking upside to further pipeline wins; convexity is preferable because the multiple already discounts a lot of good news.